Abstract:Abstract Background The unique mechanism of diabetic atherosclerosis has been a central research focus. Previous literature has reported that the inflammatory response mediated by dendritic cells (DCs) plays a vital role in the progression of atherosclerosis. The objective of the study was to explore the role of DCs in diabetes mellitus complicated by atherosclerosis. Methods ApoE −/− mice and bone marrow-derived DCs were used for in vivo and in vitro experiments, respectively. Masson’s staining and Oil-red-O staining were performed for atherosclerotic lesion assessment. The content of macrophages and DCs in plaque was visualized by immunohistochemistry. The expression of CD83 and CD86 were detected by flow cytometry. The fluctuations in the RNA levels of cytokines, chemokines, chemokine receptors and adhesions were analyzed by quantitative RT-PCR. The concentrations of IFN-γ and TNF-α were calculated using ELISA kits and the proteins were detected using western blot. Coimmunoprecipitation was used to detect protein–protein interactions . Results Compared with the ApoE −/− group, the volume of atherosclerotic plaques in the aortic root of diabetic ApoE −/− mice was significantly increased, numbers of macrophages and DCs were increased, and the collagen content in plaques decreased. The expression of CD83 and CD86 were significantly upregulated in splenic CD11c + DCs derived from mice with hyperglycemia. Increased secretion of cytokines, chemokines, chemokine receptors, intercellular cell adhesion molecule (ICAM), and vascular cell adhesion molecule (VCAM) also were observed. The stimulation of advanced glycation end products plus oxidized low-density lipoprotein, in cultured BMDCs, further activated toll-like receptor 4, protein kinase C and receptor of AGEs, and induced immune maturation of DCs through the RAGE-TLR4-PKCβ 1 signaling pathway that was bound together by intrinsic structures on the cell membrane. Administering LY333531 significantly increased the body weight of diabetic ApoE −/− mice, inhibited the immune maturation of spleen DCs, and reduced atherosclerotic plaques in diabetic ApoE −/− mice. Furthermore, the number of DCs and macrophages in atherosclerotic plaques was significantly reduced in the LY333531 group, and the collagen content was increased. Conclusions Diabetes mellitus aggravates chronic inflammation, and promotes atherosclerotic plaques in conjunction with hyperlipidemia, which at least in part through inducing the immune maturation of DCs, and its possible mechanism of action is through the RAGE-TLR4-pPKCβ 1 signaling pathway.

Evaluation of the C-domain of Heparanase During AGE-induced Macrophage Inflammatory Response.

Heparanase Induced by Advanced Glycation End Products (ages) Promotes Macrophage Migration Involving RAGE and PI3K/AKT Pathway

AGEs Increased Migration and Inflammatory Responses of Adventitial Fibroblasts Via RAGE, MAPK and NF-κB Pathways

Insulin-Attenuated Inflammatory Response of Dendritic Cells in Diabetes by Regulating RAGE-PKCβ1-IRS1-NF-κB Signal Pathway: A Study on the Anti-Inflammatory Mechanism of Insulin in Diabetes

Advanced Glycation End-Products Downregulate HoxA9EC Through Activation of Nuclear Factor Kappa B by Reciprocal Interaction

AGEs and chronic subclinical inflammation in diabetes: disorders of immune system.

Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor

Heparanase-driven Inflammation from the AGEs-stimulated Macrophages Changes the Functions of Glomerular Endothelial Cells.

Advanced Glycation End Products Promote Differentiation of CD4 + T Helper Cells Toward Pro-inflammatory Response

AGEs inhibit scavenger receptor class B type I gene expression via Smad1 in HUVECs

Blockade of PKC-beta Protects HUVEC from Advanced Glycation End Products Induced Inflammation

Advanced Glycation End Products Induce Vascular Smooth Muscle Cell-Derived Foam Cell Formation and Transdifferentiate to a Macrophage-Like State.

Unveiling the molecular basis of inflamm-aging induced by advanced glycation end products (AGEs)-modified human serum albumin (AGE-HSA) in patients with different immune-mediated diseases

Advanced Glycation End Products Enhance Macrophages Polarization into M1 Phenotype Through Activating RAGE/NF-κB Pathway

Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways

Advanced Glycation End Products (ages) Inhibit Macrophage Efferocytosis of Apoptotic Β Cells Through Binding to the Receptor for AGEs.

Advanced glycation end products enhance macrophage polarization to the M1 phenotype via the HIF-1α/PDK4 pathway.

Advanced glycation end products enhance macrophage polarization to the M1 phenotype via the HIF-1/PDK4 pathway

Effect and Mechanism of Advanced Glycosylation End Products on the Expression of Scavenger Receptor A in Human Monocyte-Derived Dendritic Cells

Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol

Dendritic cell-mediated chronic low-grade inflammation is regulated by the RAGE-TLR4-PKCβ1 signaling pathway in diabetic atherosclerosis